FDA Issues Warning to ImmunityBio Over 'False or Misleading' Anktiva Cancer Claims
IBRX has more than doubled off its 52-week low of $1.83.
Summary
The U.S. FDA has issued a warning letter to ImmunityBio, Inc. concerning "false or misleading" television advertisements and podcasts for its drug Anktiva. The FDA specifically cited claims that Anktiva can "cure" or "prevent all cancer," which are considered highly misleading. This is a material regulatory action that could significantly impact the company's reputation and the commercial prospects of Anktiva, a product highlighted for its commercial success in the recent 10-K. Traders will be watching for ImmunityBio's official response to the FDA and any potential financial penalties or restrictions on future marketing activities.
At the time of this announcement, IBRX was trading at $7.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3B. The 52-week trading range was $1.83 to $12.43. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.